In early trading on Monday, shares of Delcath Systems (DCTH) fell by 10% after the cancer drug development company reported third-quarter revenue of $20.5 million, slightly below expectations, and lowered its full-year guidance. Nonetheless, with a debt-free status and strong cash reserves, the company remains optimistic about achieving a 150% increase in treatment volume for 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.